Enhancing Access: Cross-Sector Collaboration in Healthcare

By Staff Writer

November 20, 2023

The Medicine Accessibility Challenge

High-income countries are increasingly struggling to afford medicines. New and established drugs are often too expensive and scarce. Gene and cell therapies, cancer pharmaceuticals, and orphan drugs are expensive and burden individuals and health systems.

Broken Pharma Systems

Pharmaceutical system fragmentation, especially in Europe, limits equal medicine availability. The outpatient and hospital sectors frequently have separate public bodies for medicine reimbursement and procurement. This distinction can cause differences in inpatient and outpatient medicine, which can have serious cost consequences, especially when hospitals start expensive therapy. The goal of a recent study was to determine whether cross-sectorial pharmaceutical policies improve medicine access in Europe.

Policymakers and Stakeholders

Policymakers and stakeholders are crucial to pharmaceutical reimbursement and procurement cross-sectorial collaboration. The roles include starting and assessing the collaboration. Policymakers can enable cross-sector collaboration with legal and regulatory frameworks. They can also start change and harmonise policy across industries. These policies can be developed and implemented using the skills and understanding of stakeholders. They can also promote collaboration benefits to stakeholders and the public. To be effective, these jobs require a productive atmosphere with trust, transparency, and stakeholder understanding.

Limitations and Future Plans for Cross-Sector Collaboration in Healthcare

The review focused on Europe, thus its findings may not apply to other regions. The evaluation did not examine cross-sector collaboration barriers, which would affect policy creation and implementation. Similar research in other regions and investigations of cross-sector collaboration barriers should solve these limitations. Longitudinal research are needed to assess how these agreements affect medicine access. This would strengthen evidence that cross-sector coordination improves access to inexpensive medicines.

Reference url

Recent Posts

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...
The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Pharma Industry

By Staff Writer

August 22, 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed significant concern over the new U.S.-EU Joint Framework Agreement. It is particularly worried about potential tariffs of 15% on pharmaceutical products. The organization argues these tariffs break a three...